Home Psychedelic Stock Review

Psychedelic Stock Review

Topical PTSD Drug Poised for Human Trials.

In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid...
Zappy Zapolin, Lamar Odom, Roland Rick Perry

Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.

Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our...

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in...

The Ketamine Endgame. Silo Pharmaceutical (SILO).

James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd...

The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel Topical Ketamine Delivery.

Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects

Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.

Rick Doblin, Recently Visited one of Psycheceutical's Labs. Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted...

Silo Pharma (SILO) $2.25, Now Our Favorite Psychedelic.

We Liked it at $3.50, we Love it at $2.25. Down but not out. Now trading below the...

Revive Therapeutics (RVVTF) Advancing MDMA Thermal Patch.

Two News Reports Related to Revives Upcoming Microneedle Patch Technology While we are still laser focused on Revive...
Silo Pharma, Psychedelic Stock Review, Roland Rick Perry

SILO Pharma (SILO) Gains 53%

For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun. Silo Pharma Gains 53%...

Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.

Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion)...

Latest article

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...